Male sexual function can be maintained without aromatization: Randomized placebo-controlled trial of dihydrotestosterone (DHT) in healthy, older men for 24 months

Journal of Sexual Medicine

Volumn 11, Issue 10, 2014, Pages 2562-2570

  Sartorius, Gideon A ^a,b   Ly, Lam P ^b   Handelsman, David J ^a,b  

^a ANZAC Research Institute   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Age; Androgen; Aromatase; Aromatization; DHT; Men; Obesity; Sexual Function; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PLACEBO; TESTOSTERONE;

ADULT; ANALYSIS OF VARIANCE; AROMATIZATION; ARTICLE; BODY MASS; BONE DENSITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTROGEN DEFICIENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOOD; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; TREATMENT OUTCOME; AGED; COMPLICATION; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; OBESITY; PHYSIOLOGY; SEXUALITY;

ADMINISTRATION, CUTANEOUS; AGED; ANDROGENS; BODY MASS INDEX; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; ESTRADIOL; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; OBESITY; SEXUALITY; TESTOSTERONE;

EID: 84908503845     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12550     Document Type: Article

References (55)

1. Jockenhovel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann C, Christoph A, Gooren L, Ernst M. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. Aging Male 2009;12:113-118.
2. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004;89:3813-3817.
3. Isidori AM, Buvat J, Corona G, Goldstein I, Jannini EA, Lenzi A, Porst H, Salonia A, Traish AM, Maggi M. A critical analysis of the role of testosterone in erectile function: From pathophysiology to treatment-A systematic review. Eur Urol 2014;65:99-112.
4. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf) 2005;63:280-293.
5. Handelsman DJ. Mechanisms of action of testosterone-Unraveling a Gordian knot. N Engl J Med 2013;369:1058-1059.
6. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013;369:1011-1022.
7. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ, Handelsman DJ. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: A randomized, placebo-controlled trial. Ann Intern Med 2010;153:621-632.
8. Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C. A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl 2003;24:688-698.
9. O'Leary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry MJ. A brief male sexual function inventory for urology. Urology 1995;46:697-706.
10. Harwood DT, Handelsman DJ. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta 2009;409:78-84.
11. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study. J Clin Oncol 2001;19:3750-3757.
12. Kato T, Komiya A, Suzuki H, Imamoto T, Ueda T, Ichikawa T. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol 2007;14:416-421.
13. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002;94:430-437.
14. Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, Ward J, O'Connell DL, Armstrong BK. Quality of life three years after diagnosis of localised prostate cancer: Population based cohort study. BMJ 2009;339:b4817.
15. Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A, Allan CA, Ly LP, Conway AJ, McLachlan RI, Handelsman DJ. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: The healthy man study. Clin Endocrinol (Oxf) 2012;77:755-763.
16. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: Results from the health professionals follow-up study. Ann Intern Med 2003;139:161-168.
17. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002.
18. Cleary PD, Morrissey G, Oster G. Health-related quality of life in patients with advanced prostate cancer: A multinational perspective. Qual Life Res 1995;4:207-220.
19. Handelsman DJ, Newman JD, Jimenez M, McLachlan R, Sartorius G, Jones GR. Performance of direct estradiol immunoassays with human male serum samples. Clin Chem 2014;60:510-517.
20. Zhang D, Fan C, Zhang J, Zhang CH. Nonparametric methods for measurements below detection limit. Stat Med 2009;28:700-715.
21. Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: An endocrine society position statement. J Clin Endocrinol Metab 2013;98:1376-1387.
22. McNamara KM, Harwood DT, Simanainen U, Walters KA, Jimenez M, Handelsman DJ. Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol 2010;121:611-618.
23. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci U S A 1998;95:6965-6970.
24. Toda K, Okada T, Takeda K, Akira S, Saibara T, Shiraishi M, Onishi S, Shizuta Y. Oestrogen at the neonatal stage is critical for the reproductive ability of male mice as revealed by supplementation with 17beta-oestradiol to aromatase gene (Cyp19) knockout mice. J Endocrinol 2001;168:455-463.
25. Wersinger SR, Sannen K, Villalba C, Lubahn DB, Rissman EF, De Vries GJ. Masculine sexual behavior is disrupted in male and female mice lacking a functional estrogen receptor alpha gene. Horm Behav 1997;32:176-183.
26. Ogawa S, Chan J, Chester AE, Gustafsson JA, Korach KS, Pfaff DW. Survival of reproductive behaviors in estrogen receptor beta gene-deficient (betaERKO) male and female mice. Proc Natl Acad Sci U S A 1999;96:12887-12892.
27. Ogawa S, Chester AE, Hewitt SC, Walker VR, Gustafsson JA, Smithies O, Korach KS, Pfaff DW. Abolition of male sexual behaviors in mice lacking estrogen receptors alpha and beta (alpha beta ERKO). Proc Natl Acad Sci U S A 2000;97:14737-14741.
28. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998;95:15677-15682.
29. Antal MC, Krust A, Chambon P, Mark M. Sterility and absence of histopathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci U S A 2008;105:2433-2438.
30. Dominguez-Salazar E, Bateman HL, Rissman EF. Background matters: The effects of estrogen receptor alpha gene disruption on male sexual behavior are modified by background strain. Horm Behav 2004;46:482-490.
31. Gooren LJG. Human male sexual functions do not require aromatization of testosterone: A study using tamoxifen, testolactone, and dihydrotestosterone. Arch Sex Behav 1985;14:539-548.
32. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: A prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:1467-1472.
33. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: A randomized-controlled trial. J Clin Endocrinol Metab 2011;96:430-437.
34. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001;86:4078-4088.
35. Gleeson HK, Shalet SM. Effect of aromatizable and unaromatizable androgen replacement in hypogonadal men on GH responsiveness. Clin Endocrinol (Oxf) 2009;70:109-115.
36. Chemana D, Morville R, Fiet J, Villette JM, Tabuteau F, Brerault JL, Passa P. Percutaneous absorption of 5α-dihydrotestosterone in man. II Percutaneous administration of 5α-dihydrotestosterone in hypogonadal men with idiopathic haemochromatosis; clinical, metabolic and hormonal effectiveness. Int J Androl 1982;5:595-606.
37. Barud W, Palusinski R, Makaruk B, Hanzlik J. Dihydrotestosterone treatment in men with coronary artery disease. I. Influence on sex hormones, lipid profile, insulin resistance and fibrinogen. Ann Univ Mariae Curie Sklodowska [Med] 2003;58:241-246.
38. Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR. Dimethandrolone (7alpha, 11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. J Steroid Biochem Mol Biol 2008;110:214-222.
39. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993;77:776-779.
40. Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 2001;16:2570-2577.
41. Storer TW, Woodhouse LJ, Sattler F, Singh AB, Schroeder ET, Beck K, Padero M, Mac P, Yarasheski KE, Geurts P, Willemsen A, Harms MK, Bhasin S. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 2005;90:4474-4482.
42. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 2006;17:2307-2314.
43. Chung T, Kelleher S, Liu PY, Conway AJ, Kritharides L, Handelsman DJ. Effects of testosterone and nandrolone on cardiac function: A randomized, placebo-controlled study. Clin Endocrinol (Oxf) 2007;66:235-245.
44. Crawford BA, Liu PY, Kean M, Bleasel J, Handelsman DJ. Randomised, placebo-controlled trial of androgen effects on bone and muscle in men requiring long-term systemic glucocorticoid therapy. J Clin Endocrinol Metab 2003;88:3167-3176.
45. Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, Bancroft J, Sundaram K, Moo-Young AJ, Baird DT. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab 1999;84:3556-3562.
46. Luisi M, Franchi E. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest 1980;3:305-308.
47. Guay AT, Bansal S, Heatley GJ. Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: Double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 1995;80:3546-3552.
48. Moskovic DJ, Katz DJ, Akhavan A, Park K, Mulhall JP. Clomiphene citrate is safe and effective for long-term management of hypogonadism. BJU Int 2012;110:1524-1528.
49. Balili I, Barkan A. Tamoxifen as a therapeutic agent in acromegaly. Pituitary 2013. doi:org/10.1007/s11102-013-0534-9. [Epub ahead of print].
50. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D, Bostwick D, Steiner M. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: Results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006;176:965-970, discussion 70-1.
51. Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML, Steiner M. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J Clin Oncol 2013;31:523-529.
52. Duschek EJ, Gooren LJ, Netelenbos C. Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 2004;150:539-546.
53. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res 2004;19:1518-1524.
54. McEwen BS. Sex, stress and the hippocampus: Allostasis, allostatic load and the aging process. Neurobiol Aging 2002;23:921-939.
55. Hung AJ, Stanbury MG, Shanabrough M, Horvath TL, Garcia-Segura LM, Naftolin F. Estrogen, synaptic plasticity and hypothalamic reproductive aging. Exp Gerontol 2003;38:53-59.